Erbb2 (erb-b2 receptor tyrosine kinase 2) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Erbb2 (erb-b2 receptor tyrosine kinase 2) Rattus norvegicus
Symbol: Erbb2
Name: erb-b2 receptor tyrosine kinase 2
RGD ID: 2561
Description: Enables Hsp90 protein binding activity; protein tyrosine kinase activity; and ubiquitin protein ligase binding activity. Involved in several processes, including ERBB2-ERBB4 signaling pathway; nervous system development; and positive regulation of intracellular signal transduction. Located in several cellular components, including basolateral plasma membrane; lateral loop; and postsynaptic membrane. Biomarker of congestive heart failure and median neuropathy. Human ortholog(s) of this gene implicated in several diseases, including lung cancer (multiple); mammary Paget's disease; reproductive organ cancer (multiple); stomach cancer; and urinary system cancer (multiple). Orthologous to human ERBB2 (erb-b2 receptor tyrosine kinase 2); PARTICIPATES IN mitogen activated protein kinase signaling pathway; Ras mediated signaling pathway; altered epidermal growth factor/neuregulin signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2-acetamidofluorene; 3,3',5,5'-tetrabromobisphenol A.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); C-erbB-2; epidermal growth factor receptor-related protein; HER2/neu; LOC102552659; neu; NEU proto-oncogene; p185erbB2; p185neu; proto-oncogene c-ErbB-2; proto-oncogene NEU; receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2-like; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Is Marker For: Strains:   SD-Tg(MMTV-Erbb2)1UwmRrrc  
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr81083,907,491 - 83,931,365 (+)NCBIGRCr8
mRatBN7.21083,411,197 - 83,435,078 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1083,411,313 - 83,435,078 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1088,355,647 - 88,379,493 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01087,853,732 - 87,877,578 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01083,246,384 - 83,270,230 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01086,367,596 - 86,391,728 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1086,367,596 - 86,391,728 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01086,163,531 - 86,187,663 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41087,219,157 - 87,242,919 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11087,233,617 - 87,256,603 (+)NCBI
Celera1082,158,844 - 82,182,518 (+)NCBICelera
Cytogenetic Map10q31NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
adenocarcinoma  (ISO)
amblyopia  (IEP)
Animal Disease Models  (ISO)
Animal Mammary Neoplasms  (ISO)
basal cell carcinoma  (ISO)
breast cancer  (ISS)
Breast Cancer, Familial  (ISO)
Breast Neoplasms  (ISO)
calcinosis  (ISO)
Carcinogenesis  (ISO)
cholangiocarcinoma  (ISO)
Circulating Neoplastic Cells  (ISO)
Colonic Neoplasms  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
congestive heart failure  (IEP)
Diabetic Cardiomyopathies  (IEP)
dilated cardiomyopathy  (ISO,ISS)
disease of cellular proliferation  (ISO,NAS)
Disease Progression  (ISO)
ductal carcinoma in situ  (ISO)
Endometrial Neoplasms  (ISO)
Endometrioid Carcinomas  (ISO)
esophageal carcinoma  (ISO)
Esophageal Neoplasms  (ISO)
Experimental Mammary Neoplasms  (IDA,ISO)
Experimental Neoplasms  (ISO)
Familial Visceral Neuropathy 2, Autosomal Recessive  (ISO)
gallbladder carcinoma  (ISO)
Gallbladder Neoplasms  (ISO)
gastric adenocarcinoma  (ISO)
Gastrointestinal Neoplasms  (ISO)
genetic disease  (ISO)
Germ Cell and Embryonal Neoplasms  (ISO)
head and neck squamous cell carcinoma  (ISO)
Helicobacter Infections  (ISO)
HELLP syndrome  (ISO)
high grade glioma  (ISO)
Hirschsprung's disease  (ISO,ISS)
hypertrophic cardiomyopathy 25  (ISO)
interstitial cystitis  (IEP)
invasive ductal carcinoma  (ISO)
invasive lobular carcinoma  (ISO)
Kidney Neoplasms  (ISO)
laryngeal squamous cell carcinoma  (ISO)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
mammary Paget's disease  (ISO)
median neuropathy  (IEP)
medulloblastoma  (ISO)
melanoma  (ISO)
Mouth Neoplasms  (IEP)
myelodysplastic syndrome  (ISO)
myocardial infarction  (IEP)
Myocardial Ischemia  (ISO)
Neoplasm Metastasis  (IMP,ISO)
Neoplasm Recurrence, Local  (ISO)
nephroblastoma  (ISO)
oral squamous cell carcinoma  (ISO)
ovarian cancer  (ISO)
ovarian carcinoma  (ISO)
Ovarian Neoplasms  (ISO)
ovarian serous cystadenocarcinoma  (ISO)
ovary adenocarcinoma  (ISO)
pancreatic adenocarcinoma  (ISO)
papillary renal cell carcinoma  (ISO)
papilloma  (ISO)
Parkinson's disease  (ISO)
Peripheral Nerve Injuries  (IMP)
pre-eclampsia  (ISO)
prostate adenocarcinoma  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
Recurrence  (ISO)
renal cell carcinoma  (ISO)
skin melanoma  (ISO)
Sporadic Papillary Renal Cell Carcinoma  (ISO)
stomach cancer  (ISO)
stomach carcinoma  (ISO)
Stomach Neoplasms  (ISO)
stress-related disorder  (IEP)
transitional cell carcinoma  (ISO)
urinary bladder cancer  (ISO)
Urologic Neoplasms  (ISO)
uterine cancer  (ISO)
uterine carcinosarcoma  (ISO)
Uterine Cervical Neoplasms  (ISO)
Ventilator-Induced Lung Injury  (IMP)
Wallerian Degeneration  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-Tetrandrine  (ISO)
(-)-epigallocatechin 3-gallate  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (ISO)
1,2-dimethylhydrazine  (ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-acetamidofluorene  (EXP)
2-deoxy-D-glucose  (ISO)
2-hydroxypropanoic acid  (ISO)
3,3',5,5'-tetrabromobisphenol A  (EXP)
3,3'-diindolylmethane  (ISO)
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol  (ISO)
3,7-dihydropurine-6-thione  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-Nitrobenzanthrone  (ISO)
3H-1,2-dithiole-3-thione  (EXP)
4'-epidoxorubicin  (ISO)
4-hydroxynon-2-enal  (ISO)
4-nonylphenol  (ISO)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (EXP)
acetaldehyde  (ISO)
acetylsalicylic acid  (ISO)
acrolein  (ISO)
acrylamide  (EXP,ISO)
afimoxifene  (ISO)
aflatoxin B1  (EXP)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alpha-pinene  (ISO)
amiloride  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
androgen antagonist  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
apigenin  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
baicalein  (ISO)
benzo[a]pyrene  (ISO)
Benzo[k]fluoranthene  (ISO)
benzophenanthridine  (ISO)
berberine  (ISO)
beta-hexachlorocyclohexane  (ISO)
beta-naphthoflavone  (ISO)
bifenthrin  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisdemethoxycurcumin  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bortezomib  (ISO)
bosutinib  (EXP)
butanal  (ISO)
Butylparaben  (EXP)
cadmium atom  (ISO)
caffeine  (ISO)
canertinib  (ISO)
cannabidiol  (ISO)
capsaicin  (ISO)
captan  (ISO)
carbamazepine  (ISO)
carboplatin  (ISO)
CGP 52608  (ISO)
chloroquine  (ISO)
chlorothalonil  (ISO)
choline  (ISO)
chromium(6+)  (ISO)
cisplatin  (ISO)
clozapine  (EXP)
cobalt dichloride  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
copper(II) sulfate  (ISO)
cordycepin  (ISO)
coumarin  (ISO)
coumestrol  (ISO)
crocidolite asbestos  (ISO)
Cruentaren A  (ISO)
Cuprizon  (EXP)
curcumin  (ISO)
cycloheximide  (ISO)
cyclophosphamide  (ISO)
cyclosporin A  (ISO)
cyhalothrin  (ISO)
D-glucose  (ISO)
delphinidin  (ISO)
demethoxycurcumin  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
dibenz[a,h]anthracene  (ISO)
Dibutyl phosphate  (ISO)
dibutyl phthalate  (EXP)
dimethylarsinic acid  (EXP)
dioxygen  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
dutasteride  (ISO)
elemental selenium  (ISO)
endosulfan  (EXP,ISO)
enzacamene  (EXP)
epoxiconazole  (EXP)
ethanol  (ISO)
ethyl trans-caffeate  (ISO)
etoposide  (ISO)
fipronil  (EXP)
fisetin  (ISO)
fludioxonil  (ISO)
fluvalinate  (ISO)
folic acid  (ISO)
folpet  (ISO)
formaldehyde  (ISO)
fulvestrant  (ISO)
furan  (EXP)
gefitinib  (ISO)
geldanamycin  (ISO)
genistein  (ISO)
gentamycin  (EXP)
glucose  (ISO)
haloperidol  (EXP)
Heptachlor epoxide  (ISO)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
Indeno[1,2,3-cd]pyrene  (ISO)
indometacin  (ISO)
irinotecan  (EXP)
iron(2+) sulfate (anhydrous)  (ISO)
kahweol  (ISO)
L-methionine  (ISO)
lactacystin  (ISO)
lapatinib  (ISO)
lead(0)  (ISO)
lignan  (ISO)
linuron  (EXP)
lithium chloride  (ISO)
LY294002  (ISO)
masoprocol  (ISO)
mechlorethamine  (ISO)
mercaptopurine  (EXP)
methotrexate  (ISO)
mitoxantrone  (ISO)
MK-2206  (ISO)
N-acetylcysteamine  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-ethyl-N-nitrosourea  (EXP)
N-methyl-N'-nitro-N-nitrosoguanidine  (ISO)
nitrogen mustard  (ISO)
orlistat  (ISO)
Oxyfluorfen  (ISO)
ozone  (ISO)
paclitaxel  (ISO)
palmatine  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
perfluorooctane-1-sulfonic acid  (EXP)
perfluorooctanoic acid  (ISO)
permethrin  (ISO)
phenylmercury acetate  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
Pirarubicin  (ISO)
platycodin D  (ISO)
prochloraz  (EXP)
procymidone  (EXP)
purine-6-thiol  (EXP)
quercetin  (ISO)
quinazolines  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
reparixin  (ISO)
reserpine  (EXP)
resveratrol  (ISO)
Rhein  (ISO)
risperidone  (EXP)
romidepsin  (ISO)
SB 203580  (ISO)
SB 431542  (ISO)
selenium atom  (ISO)
silicon dioxide  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (EXP,ISO)
SR 144528  (ISO)
sulfadimethoxine  (EXP)
sulindac sulfide  (ISO)
sulindac sulfone  (ISO)
tamoxifen  (ISO)
tanespimycin  (ISO)
temozolomide  (ISO)
tephrosin  (ISO)
tert-butyl hydroperoxide  (ISO)
tetrachloromethane  (EXP)
tetraphene  (ISO)
thalidomide  (ISO)
Thiotepa  (ISO)
titanium dioxide  (ISO)
tributylstannane  (ISO)
trichloroethene  (EXP,ISO)
trimellitic anhydride  (ISO)
triphenyl phosphate  (ISO)
tyrphostin AG 1478  (ISO)
undecane  (EXP)
urethane  (ISO)
valproic acid  (ISO)
vincaleukoblastine  (ISO)
vinclozolin  (EXP)
vitamin E  (ISO)
vorinostat  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
axon regeneration  (IMP)
cell surface receptor protein tyrosine kinase signaling pathway  (ISO)
cell surface receptor signaling pathway  (ISO)
cellular response to epidermal growth factor stimulus  (IEA,ISO,ISS)
cellular response to growth factor stimulus  (ISO,ISS)
cellular response to mechanical stimulus  (IEP)
ERBB2-EGFR signaling pathway  (IEA,ISO)
ERBB2-ERBB3 signaling pathway  (IEA,ISO)
ERBB2-ERBB4 signaling pathway  (IDA,IEA,ISO)
estrous cycle  (IMP)
female pregnancy  (IEP)
glial cell differentiation  (IGI)
heart development  (IEA,ISO)
immature T cell proliferation in thymus  (IEA,ISO)
intracellular signal transduction  (ISO,ISS)
liver development  (IEP)
mammary gland involution  (IEP)
motor neuron axon guidance  (IEA,ISO)
multicellular organismal response to stress  (IEP)
myelination  (IEA,ISO)
negative regulation of apoptotic process  (IBA,IMP)
negative regulation of immature T cell proliferation in thymus  (IEA,ISO)
nervous system development  (ISO)
neurogenesis  (IBA)
neuromuscular junction development  (IEA,ISO)
neuron differentiation  (IBA)
neurotransmitter receptor localization to postsynaptic specialization membrane  (IEA,ISO)
oligodendrocyte differentiation  (IEA,ISO)
peripheral nervous system development  (IMP,ISO)
phosphatidylinositol 3-kinase/protein kinase B signal transduction  (IEA,ISO)
positive regulation of cell adhesion  (IEA,ISO)
positive regulation of cell growth  (IEA,ISO,ISS)
positive regulation of cell population proliferation  (IBA,IMP)
positive regulation of epithelial cell proliferation  (IEA,ISO)
positive regulation of gene expression  (ISO)
positive regulation of MAPK cascade  (IBA,IMP)
positive regulation of membrane permeability  (IMP)
positive regulation of neural precursor cell proliferation  (IMP)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction  (IMP)
positive regulation of protein phosphorylation  (IEA,ISO)
positive regulation of protein targeting to membrane  (IEA,ISO,ISS)
positive regulation of Ras protein signal transduction  (IMP)
positive regulation of Rho protein signal transduction  (IEA,ISO)
positive regulation of transcription by RNA polymerase I  (IEA,ISO,ISS)
positive regulation of translation  (IEA,ISO,ISS)
protein autophosphorylation  (IDA)
regulation of cell differentiation  (TAS)
regulation of cell population proliferation  (TAS)
regulation of ERK1 and ERK2 cascade  (IEA,ISO,ISS)
regulation of microtubule-based process  (IEA,ISO,ISS)
response to axon injury  (IDA)
response to dexamethasone  (IEP)
response to muscle activity  (IEP)
response to progesterone  (IEP)
response to vitamin D  (IEP)
response to xenobiotic stimulus  (IEP)
Schwann cell development  (IEA,ISO)
semaphorin-plexin signaling pathway  (IEA,ISO)
signal transduction  (ISO)
skeletal muscle tissue development  (IEP)
sympathetic nervous system development  (IMP)
tongue development  (IEP)
wound healing  (IEA,ISO)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype

References - curated
# Reference Title Reference Citation
1. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Bansal N, etal., Cancer Control. 2009 Jan;16(1):8-13.
2. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Barnes NL, etal., Clin Cancer Res. 2005 Mar 15;11(6):2163-8.
3. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. Begnami MD, etal., J Clin Oncol. 2011 Aug 1;29(22):3030-6. doi: 10.1200/JCO.2010.33.6313. Epub 2011 Jun 27.
4. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. Bei R, etal., J Pathol. 2001 Oct;195(3):343-8. doi: 10.1002/path.965.
5. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Bersell K, etal., Cell. 2009 Jul 23;138(2):257-70. doi: 10.1016/j.cell.2009.04.060.
6. HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study. Bianco MK and Vasef MA, Diagn Mol Pathol. 2006 Sep;15(3):131-5.
7. Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells. Brown KD and Hansen MR, Otol Neurotol. 2008 Jan;29(1):79-85.
8. Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma. Bussu F, etal., Laryngoscope. 2012 Aug;122(8):1724-33. doi: 10.1002/lary.23311. Epub 2012 May 1.
9. Exercise training activates neuregulin 1/ErbB signaling and promotes cardiac repair in a rat myocardial infarction model. Cai MX, etal., Life Sci. 2016 Mar 15;149:1-9. doi: 10.1016/j.lfs.2016.02.055. Epub 2016 Feb 15.
10. ErbB2 and its ligand Muc4 (sialomucin complex) in rat lacrimal gland. Carraway KL, etal., Adv Exp Med Biol. 2002;506(Pt A):289-95.
11. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. Carroll SL, etal., J Neurosci 1997 Mar 1;17(5):1642-59.
12. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Carver RS, etal., Gastroenterology. 2002 Dec;123(6):2017-27.
13. Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Chan R, etal., Development 2004 Nov;131(22):5551-60. Epub 2004 Oct 20.
14. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma. Chen HY, etal., Oncotarget. 2016 Feb 23;7(8):9017-25. doi: 10.18632/oncotarget.7029.
15. Neuregulin-1-ErbB signaling promotes microglia activation contributing to mechanical allodynia of cyclophosphamide-induced cystitis. Chen JL, etal., Neurourol Urodyn. 2019 Jun;38(5):1250-1260. doi: 10.1002/nau.24005. Epub 2019 Apr 15.
16. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Cho HS, etal., Nature 2003 Feb 13;421(6924):756-60.
17. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Crone SA, etal., Neuron 2003 Jan 9;37(1):29-40.
18. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Dahl Steffensen K, etal., Int J Oncol. 2008 Jul;33(1):195-204.
19. Chronic administration of calcitriol enhanced neuregulin-1/ErbB signaling in rat myocardium. Dang R, etal., Pharmazie. 2016 Apr;71(4):192-5.
20. Chronic stress and excessive glucocorticoid exposure both lead to altered Neuregulin-1/ErbB signaling in rat myocardium. Dang R, etal., Steroids. 2016 Aug;112:47-53. doi: 10.1016/j.steroids.2016.04.011. Epub 2016 Apr 29.
21. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Dankort D, etal., Mol Cell Biol 2001 Mar;21(5):1540-51.
22. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Dankort DL, etal., Mol Cell Biol. 1997 Sep;17(9):5410-25.
23. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. Darcy KM, etal., J Histochem Cytochem. 2000 Jan;48(1):63-80.
24. Neuregulin 1 growth factors regulate proliferation but not apoptosis of a CNS neuronal progenitor cell line. Edwards JM and Bottenstein JE, Brain Res. 2006 Sep 7;1108(1):63-75. doi: 10.1016/j.brainres.2006.06.025. Epub 2006 Jul 21.
25. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Ejskjaer K, etal., Gynecol Oncol. 2007 Jan;104(1):158-67. Epub 2006 Sep 7.
26. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Engelsen IB, etal., Int J Oncol. 2008 Feb;32(2):307-16.
27. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. Frohnert PW, etal., Glia. 2003 Aug;43(2):104-18.
28. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Fuchs I, etal., Anticancer Res. 2007 Mar-Apr;27(2):959-63.
29. A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool. Garratt AN, etal., J Cell Biol 2000 Mar 6;148(5):1035-46.
30. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
31. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
32. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Grushko TA, etal., Gynecol Oncol. 2008 Jan;108(1):3-9. Epub 2007 Oct 18.
33. Microanatomy of axon/glial signaling during Wallerian degeneration. Guertin AD, etal., J Neurosci. 2005 Mar 30;25(13):3478-87.
34. Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy. Gui C, etal., Cardiovasc Pathol. 2012 Sep-Oct;21(5):414-20. doi: 10.1016/j.carpath.2011.12.006. Epub 2012 Jan 28.
35. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Guy CT, etal., Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82.
36. The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma. He Q, etal., Mol Biol Rep. 2008 Apr 22;.
37. Analysis of genetic changes in rat endometrial carcinomas by means of comparative genomic hybridization. Helou K, etal., Cancer Genet Cytogenet 2001 Jun;127(2):118-27.
38. Functional integrity of ErbB-4/-2 tyrosine kinase receptor complex in the hypothalamus is required for maintaining normal reproduction in young adult female rats. Hou J, etal., Endocrinology. 2002 May;143(5):1901-12.
39. Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins. Howard PL, etal., Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11267-72. Epub 2003 Sep 17.
40. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Ignatiadis M, etal., Clin Breast Cancer. 2007 Dec;7(11):883-9.
41. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. Iwakura Y, etal., J Neurochem. 2005 May;93(4):974-83.
42. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Jalali Nadoushan MR, etal., Urol J. 2007 Summer;4(3):151-4.
43. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Junttila TT, etal., Clin Cancer Res. 2003 Nov 1;9(14):5346-57.
44. The impact of Helicobacter pylori on EGF, EGF receptor, and the c-erb-B2 expression. Jurkowska G, etal., Adv Med Sci. 2014 Sep;59(2):221-6. doi: 10.1016/j.advms.2014.01.006. Epub 2014 Jun 9.
45. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Kim A, etal., Breast Cancer Res. 2005;7(5):R708-18. Epub 2005 Jul 6.
46. Identification of target antigens in specific immunotherapy for renal cell carcinoma. Komohara Y, etal., J Urol. 2007 Mar;177(3):1157-62.
47. Neuregulin 1 is a pronociceptive cytokine that is regulated by progesterone in the spinal cord: implications for sex specific pain modulation. Lacroix-Fralish ML, etal., Eur J Pain. 2008 Jan;12(1):94-103. Epub 2007 Apr 24.
48. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Lebrasseur NK, etal., Am J Physiol Cell Physiol. 2003 May;284(5):C1149-55. Epub 2003 Jan 2.
49. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Lee CM, etal., Gynecol Oncol. 2005 Nov;99(2):415-21. Epub 2005 Sep 12.
50. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Lemmens K, etal., Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H931-42. doi: 10.1152/ajpheart.00385.2010. Epub 2010 Dec 24.
51. The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells. Liu W, etal., Biochim Biophys Acta. 2007 Jul;1772(7):737-47. Epub 2007 May 5.
52. Expression of HER-2/neu in testicular tumors. Mandoky L, etal., Anticancer Res. 2003 Jul-Aug;23(4):3447-51.
53. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors. Masuelli L, etal., Int J Oncol. 2007 Feb;30(2):381-92.
54. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Matsubara H, etal., Oncol Rep. 2008 Jan;19(1):57-63.
55. Erb and c-Kit receptors have distinctive patterns of expression in adult and developing taste papillae and taste buds. McLaughlin SK J Neurosci. 2000 Aug 1;20(15):5679-88.
56. Elevated serum levels of the c-erbB-2 encoded oncoprotein fragment in cases of pure preeclampsia and HELLP syndrome. Meden H, etal., J Obstet Gynaecol Res. 1997 Apr;23(2):213-7.
57. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Memon AA, etal., Br J Cancer. 2006 Jun 5;94(11):1703-9.
58. Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast. Menezes MV, etal., Sao Paulo Med J. 2006 May 4;124(3):121-4.
59. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
60. Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Moscoso LM, etal., Dev Biol. 1995 Nov;172(1):158-69.
61. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Nagasawa J, etal., Int J Urol. 2006 May;13(5):587-92.
62. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
63. Denervation and reinnervation of adult skeletal muscle modulate mRNA expression of neuregulin-1 and ErbB receptors. Nicolino S, etal., Microsurgery. 2009;29(6):464-72. doi: 10.1002/micr.20636.
64. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. O'Regan RM, etal., Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2255-63.
65. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
66. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Ozcelik C, etal., Proc Natl Acad Sci U S A 2002 Jun 25;99(13):8880-5. Epub 2002 Jun 18.
67. New driver mutations in non-small-cell lung cancer. Pao W and Girard N, Lancet Oncol. 2011 Feb;12(2):175-80.
68. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Papadopoulou E, etal., Neoplasma. 2008;55(2):113-21.
69. Sequential signaling through Notch1 and erbB receptors mediates radial glia differentiation. Patten BA, etal., J Neurosci 2003 Jul 9;23(14):6132-40.
70. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. Peng X, etal., J Biol Chem. 2005 Apr 1;280(13):13148-52. Epub 2005 Jan 25.
71. Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Peoples GE, etal., Clin Cancer Res. 2008 Feb 1;14(3):797-803.
72. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
73. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
74. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
75. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. Price-Schiavi SA, etal., J Cell Physiol. 2005 Apr;203(1):44-53.
76. Immunohistochemical evaluation of the HER-2 protein in the infiltrative lobular breast cancer. Radovic S, etal., Med Arh. 2006;60(4):213-6.
77. GOA pipeline RGD automated data pipeline
78. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
79. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
80. Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation. Rohrbach S, etal., Basic Res Cardiol. 2005 May;100(3):240-9. Epub 2005 Feb 3.
81. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Rohrbach S, etal., Circulation. 1999 Jul 27;100(4):407-12.
82. ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult mice. Ronchi G, etal., PLoS One. 2013;8(2):e56282. doi: 10.1371/journal.pone.0056282. Epub 2013 Feb 21.
83. Association between the HER2 expression and histological differentiation in Wilms tumor. Salem M, etal., Pediatr Surg Int. 2006 Nov;22(11):891-6.
84. The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling. Scheving LA, etal., Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G16-25.
85. Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model. Settle M, etal., Oncogene. 2003 Apr 3;22(13):1916-26.
86. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. Silva SD, etal., Oral Dis. 2010 Nov;16(8):774-80. doi: 10.1111/j.1601-0825.2010.01687.x.
87. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Singh AB and Harris RC, Cell Signal. 2005 Oct;17(10):1183-93.
88. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
89. Multiple cis- and trans-acting elements involved in regulation of the neu gene. Suen TC and Hung MC, Mol Cell Biol 1990 Dec;10(12):6306-15.
90. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Taniyama K, etal., Breast Cancer. 2008 Feb 9;.
91. ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Thomasson M, etal., Acta Oncol. 2004;43(5):453-9.
92. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Tsai YS, etal., Urology. 2005 Dec;66(6):1197-202.
93. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. Tuefferd M, etal., PLoS ONE. 2007 Nov 7;2(11):e1138.
94. Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats. Vairaktaris E, etal., J Cancer Res Clin Oncol. 2008 Mar;134(3):337-44. Epub 2007 Aug 18.
95. HER-2/neu oncogene sequence revisited. Venanzi FM, etal., J Natl Cancer Inst 2002 Dec 4;94(23):1808-9.
96. Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Wang B, etal., Cancer Res. 1991 Oct 15;51(20):5649-54.
97. Correlation of Mammographic Calcifications with HER-2/neu Overexpression in Primary Breast Carcinomas. Wang X, etal., J Digit Imaging. 2008 Feb 7;.
98. Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Wang XD, etal., Int J Neuropsychopharmacol. 2008 Jan 10;:1-9.
99. Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene. Watson PA, etal., Cancer Cell. 2002 Jul;2(1):67-79.
100. Effect of regulation of the NRG1/ErbB4 signaling pathway on the visual cortex synaptic plasticity of amblyopic adult rats. Xu L, etal., J Biochem Mol Toxicol. 2021 Sep;35(9):e22841. doi: 10.1002/jbt.22841. Epub 2021 Jul 17.
101. Identification and characterization of a novel enhancer for the rat neu promoter. Yan DH and Hung MC, Mol Cell Biol 1991 Apr;11(4):1875-82.
102. HER2 Signaling Implicated in Regulating Alveolar Epithelial Permeability with Cyclic Stretch. Yehya N, etal., Int J Mol Sci. 2019 Feb 22;20(4):948. doi: 10.3390/ijms20040948.
103. Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. Zhu X, etal., EMBO J. 1995 Dec 1;14(23):5842-8.
Additional References at PubMed
PMID:1346763   PMID:1682063   PMID:2025425   PMID:3945311   PMID:7514177   PMID:7556068   PMID:8104327   PMID:9362461   PMID:9551081   PMID:9685399   PMID:10572067   PMID:10655525  
PMID:12000754   PMID:12646923   PMID:15044753   PMID:15051716   PMID:15306553   PMID:15489334   PMID:15520177   PMID:15899872   PMID:16122940   PMID:16168101   PMID:16170374   PMID:16230479  
PMID:16314522   PMID:16432850   PMID:16698793   PMID:16843263   PMID:16889796   PMID:17148612   PMID:17203384   PMID:17585012   PMID:18056992   PMID:18473736   PMID:18535289   PMID:18705011  
PMID:18845940   PMID:19010331   PMID:19139271   PMID:19331811   PMID:19372587   PMID:19650109   PMID:19806804   PMID:20010870   PMID:20049896   PMID:20180588   PMID:20220087   PMID:20392965  
PMID:20565902   PMID:20684269   PMID:20937854   PMID:21106881   PMID:21203579   PMID:21255571   PMID:21480528   PMID:21555369   PMID:21791570   PMID:22019888   PMID:22214165   PMID:22253826  
PMID:22385253   PMID:22564389   PMID:22733765   PMID:22815787   PMID:22912742   PMID:23301073   PMID:23319611   PMID:23380500   PMID:23382219   PMID:23436906   PMID:23530877   PMID:23553667  
PMID:23555577   PMID:23826343   PMID:23968588   PMID:24364879   PMID:25215939   PMID:25978692   PMID:26116536   PMID:26254336   PMID:26261492   PMID:26310459   PMID:26985693   PMID:27083286  
PMID:27134172   PMID:29568012   PMID:32890875   PMID:33705930  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr81083,907,491 - 83,931,365 (+)NCBIGRCr8
mRatBN7.21083,411,197 - 83,435,078 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1083,411,313 - 83,435,078 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1088,355,647 - 88,379,493 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01087,853,732 - 87,877,578 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01083,246,384 - 83,270,230 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01086,367,596 - 86,391,728 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1086,367,596 - 86,391,728 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01086,163,531 - 86,187,663 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41087,219,157 - 87,242,919 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11087,233,617 - 87,256,603 (+)NCBI
Celera1082,158,844 - 82,182,518 (+)NCBICelera
Cytogenetic Map10q31NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381739,688,094 - 39,728,658 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1739,687,914 - 39,730,426 (+)EnsemblGRCh38hg38GRCh38
GRCh371737,844,347 - 37,884,911 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361735,097,919 - 35,138,441 (+)NCBINCBI36Build 36hg18NCBI36
Build 341735,109,779 - 35,138,441NCBI
Celera1734,504,111 - 34,544,648 (+)NCBICelera
Cytogenetic Map17q12NCBI
HuRef1733,638,318 - 33,678,659 (+)NCBIHuRef
CHM1_11738,080,177 - 38,120,667 (+)NCBICHM1_1
T2T-CHM13v2.01740,551,660 - 40,592,218 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm391198,303,310 - 98,328,542 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1198,303,296 - 98,328,542 (+)EnsemblGRCm39 Ensembl
GRCm381198,412,484 - 98,437,716 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1198,412,470 - 98,437,716 (+)EnsemblGRCm38mm10GRCm38
MGSCv371198,273,798 - 98,299,030 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361198,228,574 - 98,253,806 (+)NCBIMGSCv36mm8
Celera11108,066,701 - 108,091,920 (+)NCBICelera
Cytogenetic Map11DNCBI
cM Map1161.75NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_00495545114,442,816 - 14,459,379 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495545114,442,816 - 14,456,009 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan1-v21925,226,889 - 25,267,330 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11727,121,704 - 27,162,125 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01717,560,337 - 17,600,808 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11717,777,434 - 17,817,735 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1717,777,434 - 17,805,862 (-)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1922,760,373 - 22,785,367 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl922,759,256 - 22,785,294 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha922,233,500 - 22,257,730 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0923,553,798 - 23,578,971 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl923,553,919 - 23,606,691 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1922,327,366 - 22,351,570 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0922,588,363 - 22,612,587 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0922,713,484 - 22,737,693 (-)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440560222,165,101 - 22,188,079 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493649014,887,043 - 14,909,956 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_00493649014,887,062 - 14,910,038 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1222,590,725 - 22,621,351 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11222,591,621 - 22,621,384 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21223,049,123 - 23,069,842 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.11666,435,488 - 66,464,993 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1666,434,251 - 66,464,952 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607737,344,961 - 37,374,824 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046247953,373,000 - 3,391,602 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247953,373,313 - 3,391,509 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Erbb2
113 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:494
Count of miRNA genes:218
Interacting mature miRNAs:248
Transcripts:ENSRNOT00000009114, ENSRNOT00000049070
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
61427Cia16Collagen induced arthritis QTL 163.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)10635789696121100Rat
2303118Mamtr7Mammary tumor resistance QTL 70.003mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)109658275104670812Rat
2301967Cm73Cardiac mass QTL 734.55heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)101448701189062041Rat
631268Cia21Collagen induced arthritis QTL 213.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1014487011104060283Rat
2316949Gluco60Glucose level QTL 603.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1014487011107057807Rat
1554317Bmd4Bone mineral density QTL 49.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)101981604299406971Rat
724556Pur2Proteinuria QTL 25.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)102242750090627625Rat
61354Pia10Pristane induced arthritis QTL 100.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
631267Cia20Collagen induced arthritis QTL 203.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
61325Aia5Adjuvant induced arthritis QTL 50.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
1298069Bp168Blood pressure QTL 1685.5blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)102652195798003205Rat
631542Bp82Blood pressure QTL 826.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)102652195798952741Rat
1331791Cm31Cardiac mass QTL 313.84606heart mass (VT:0007028)heart wet weight (CMO:0000069)1029299504107211142Rat
1576308Schws1Schwannoma susceptibility QTL 10.0041nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)1040035094102359817Rat
631269Cia22Collagen induced arthritis QTL 228.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631270Cia23Collagen induced arthritis QTL 233.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631552Vetf2Vascular elastic tissue fragility QTL 24.50.0002aorta elastic tissue integrity trait (VT:0010556)artery internal elastic lamina non-tumorous lesion count (CMO:0001913)104114263386142633Rat
61463Bp12Blood pressure QTL 126.30.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104133325886333258Rat
1298078Stresp5Stress response QTL 52.990.00025blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1042045676104670812Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)14232313287323132Rat
70198BpQTLcluster9Blood pressure QTL cluster 92.94arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)104232313287323132Rat
9589030Epfw9Epididymal fat weight QTL 919.240.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)104444169989441699Rat
7411614Foco18Food consumption QTL 180.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)104444169989441699Rat
8694173Bw149Body weight QTL 1494.380.001body mass (VT:0001259)body weight gain (CMO:0000420)104444169989441699Rat
2300218Hpcl2Hepatic cholesterol level QTL 2liver cholesterol amount (VT:0010498)liver cholesterol level (CMO:0001597)104502965095600334Rat
631547Bp87Blood pressure QTL 874.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104736947092369470Rat
1549846Scl47Serum cholesterol level QTL 473.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)105057470795574707Rat
70364Bp72Blood pressure QTL 72arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)105112110096121100Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1051770177107211142Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1051770177107211142Rat
1359017Hrtrt21Heart rate QTL 212.4heart pumping trait (VT:2000009)heart rate (CMO:0000002)105177294096772940Rat
631530Tls3T-lymphoma susceptibility QTL 300.0001thymus integrity trait (VT:0010555)percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911)105177461295600334Rat
631535Cm51Cardiac mass QTL 513heart mass (VT:0007028)calculated heart weight (CMO:0000073)105178628291669536Rat
70171Cari1Carrageenan-induced inflammation QTL 14.90.0005hypodermis integrity trait (VT:0010550)inflammatory exudate volume (CMO:0001429)1053797385107211142Rat
70164Bw21Body weight QTL 214.360.00005body mass (VT:0001259)body weight (CMO:0000012)105379749498952626Rat
1354608Cm33Cardiac mass QTL 332.8heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)105480929299809292Rat
2312662Slep8Serum leptin concentration QTL 80.05blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)1057134272102134272Rat
2312668Scl65Serum cholesterol level QTL 650.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1057134272102134272Rat
2312672Insul15Insulin level QTL 150.01blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1057134272102134272Rat
1549831Bss6Bone structure and strength QTL 64lumbar vertebra strength trait (VT:0010574)vertebra ultimate force (CMO:0001678)1057576521102576521Rat
2293698Bss43Bone structure and strength QTL 435.330.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1059209888104209888Rat
2306970Anxrr22Anxiety related response QTL 225.95fear/anxiety-related behavior trait (VT:1000241)number of periods of voluntary immobility (CMO:0001045)106134527698211570Rat
6893336Cm75Cardiac mass QTL 750.10.87heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)106134527699703528Rat
1558643Cm44Cardiac mass QTL 444.80.0000368heart mass (VT:0007028)heart wet weight (CMO:0000069)106134527699703528Rat
2313103Bss80Bone structure and strength QTL 8020.0001tibia strength trait (VT:1000284)tibia midshaft endosteal cross-sectional area (CMO:0001716)1062057807107057807Rat
2313105Bss79Bone structure and strength QTL 791.80.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)1062057807107057807Rat
61449Ciaa2CIA Autoantibody QTL 27.1blood autoantibody amount (VT:0003725)calculated serum anti-type 2 collagen antibody titer (CMO:0001279)1063221094107211142Rat
1357344Bp249Blood pressure QTL 2490.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)106674365598003205Rat
2317029Aia19Adjuvant induced arthritis QTL 192.98joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)1066978955107211142Rat
2317039Aia6Adjuvant induced arthritis QTL 64.31joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)1066978955107211142Rat
10450498Bp384Blood pressure QTL 3840.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1067750049107211142Rat
1642980Bp300Blood pressure QTL 300arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068383129107211142Rat
61396Bp9Blood pressure QTL 94.80.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068420376107211142Rat
2300172Bmd57Bone mineral density QTL 579.80.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1069738412107211142Rat
2293646Bss25Bone structure and strength QTL 2510.960.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1069738412107211142Rat
2293663Bss33Bone structure and strength QTL 339.340.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1069738412107211142Rat
6893366Bw106Body weight QTL 1060.30.47body mass (VT:0001259)body weight (CMO:0000012)1070199100107211142Rat
70193Mcs7Mammary carcinoma susceptibility QTL 72.38mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1072224939107211142Rat
2298548Neuinf7Neuroinflammation QTL 73.4nervous system integrity trait (VT:0010566)spinal cord RT1-B protein level (CMO:0002132)1072224939107211142Rat
2306793Ean5Experimental allergic neuritis QTL 54.7nervous system integrity trait (VT:0010566)IFNG-secreting splenocyte count (CMO:0002122)107255241693995749Rat
12880053Cm104Cardiac mass QTL 1040.009heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)107345299283463334Rat
1358188Ept9Estrogen-induced pituitary tumorigenesis QTL 93.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
2292617Ept18Estrogen-induced pituitary tumorigenesis QTL 183.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
12880050Am10Aortic mass QTL 100.016aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)107437208484007272Rat
1579919Bp281Blood pressure QTL 2810.01arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107437208494965338Rat
631537Oia4Oil induced arthritis QTL 4joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)107563188787055282Rat
2325836Bp346Blood pressure QTL 3460.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107624608584007272Rat
10450495Bp383Blood pressure QTL 3830.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107624608594965338Rat
2292438Bp311Blood pressure QTL 311arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1076246085107211142Rat
1302404Cia27Collagen induced arthritis QTL 272.60.0045joint integrity trait (VT:0010548)experimental arthritis severity measurement (CMO:0001459)1076452683107211142Rat
4889492Pancm2Pancreatic morphology QTL 23.2pancreatic beta cell morphology trait (VT:0005217)ratio of insulin-positive cell area to total area of splenic region of pancreas (CMO:0001814)1076748906107211142Rat
724516Uae17Urinary albumin excretion QTL 173.6urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)107821062285220348Rat
1300107Rf18Renal function QTL 183.41urine output (VT:0003620)timed urine volume (CMO:0000260)107877551698279596Rat
1358915Stresp7Stress response QTL 73.52blood norepinephrine amount (VT:0005663)plasma norepinephrine level (CMO:0001010)107889965587307728Rat
634354Rends3Renal damage susceptibility QTL 30.05kidney blood vessel morphology trait (VT:0000530)organ lesion measurement (CMO:0000677)107981378985160854Rat
631555Bp134Blood pressure QTL 1340.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)108051528791230079Rat
6893357Bw102Body weight QTL 1020.50.36body mass (VT:0001259)body weight (CMO:0000012)1080515287101325465Rat
2303589Bw87Body weight QTL 872body mass (VT:0001259)body weight (CMO:0000012)1081285008107211142Rat
4889948Bss91Bone structure and strength QTL 914tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)108256485692369470Rat
2317754Glom25Glomerulus QTL 253.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)1082685200107211142Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21083,410,964 - 83,411,164 (+)MAPPERmRatBN7.2
Rnor_6.01086,367,248 - 86,367,447NCBIRnor6.0
Rnor_5.01086,163,183 - 86,163,382UniSTSRnor5.0
RGSC_v3.41087,218,808 - 87,219,008RGDRGSC3.4
RGSC_v3.41087,218,809 - 87,219,008UniSTSRGSC3.4
RGSC_v3.11087,233,178 - 87,233,378RGD
Celera1082,158,496 - 82,158,695UniSTS
Cytogenetic Map10q32.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21083,410,972 - 83,411,162 (+)MAPPERmRatBN7.2
Rnor_6.01086,367,256 - 86,367,445NCBIRnor6.0
Rnor_5.01086,163,191 - 86,163,380UniSTSRnor5.0
RGSC_v3.41087,218,817 - 87,219,006UniSTSRGSC3.4
Celera1082,158,504 - 82,158,693UniSTS
Cytogenetic Map10q32.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21083,433,502 - 83,433,602 (+)MAPPERmRatBN7.2
Rnor_6.01086,390,153 - 86,390,252NCBIRnor6.0
Rnor_6.01084,844,555 - 84,844,654NCBIRnor6.0
Rnor_5.01084,634,322 - 84,634,421UniSTSRnor5.0
Rnor_5.01086,186,088 - 86,186,187UniSTSRnor5.0
RGSC_v3.41087,241,344 - 87,241,443UniSTSRGSC3.4
Celera1082,180,943 - 82,181,042UniSTS
Cytogenetic Map10q32.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21083,434,973 - 83,435,147 (+)MAPPERmRatBN7.2
Rnor_6.01086,391,624 - 86,391,797NCBIRnor6.0
Rnor_6.01084,846,026 - 84,846,199NCBIRnor6.0
Rnor_5.01086,187,559 - 86,187,732UniSTSRnor5.0
Rnor_5.01084,635,793 - 84,635,966UniSTSRnor5.0
RGSC_v3.41087,242,815 - 87,242,988UniSTSRGSC3.4
Celera1082,182,414 - 82,182,587UniSTS
RH 3.4 Map10840.5UniSTS
Cytogenetic Map10q31UniSTS
Cytogenetic Map10q32.1UniSTS

Related Rat Strains
The following Strains have been annotated to Erbb2


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 26 2 2 2 4 23 28 3
Low 17 36 21 19 21 7 10 68 12 13 8 7
Below cutoff 19 18 18 1 1 2 1


RefSeq Acc Id: ENSRNOT00000009114   ⟹   ENSRNOP00000009116
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1086,367,687 - 86,391,042 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000049070   ⟹   ENSRNOP00000040591
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1083,411,313 - 83,435,078 (+)Ensembl
Rnor_6.0 Ensembl1086,367,596 - 86,391,728 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000071765   ⟹   ENSRNOP00000064298
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1084,838,264 - 84,845,288 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000078744   ⟹   ENSRNOP00000068582
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1086,367,710 - 86,390,886 (+)Ensembl
RefSeq Acc Id: NM_017003   ⟹   NP_058699
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
GRCr81083,907,601 - 83,931,365 (+)NCBI
mRatBN7.21083,411,313 - 83,435,078 (+)NCBI
Rnor_6.01086,367,596 - 86,391,728 (+)NCBI
Rnor_5.01086,163,531 - 86,187,663 (+)NCBI
RGSC_v3.41087,219,157 - 87,242,919 (+)RGD
Celera1082,158,844 - 82,182,518 (+)NCBI
RefSeq Acc Id: XM_039085176   ⟹   XP_038941104
Rat AssemblyChrPosition (strand)Source
GRCr81083,913,957 - 83,931,022 (+)NCBI
mRatBN7.21083,417,098 - 83,434,236 (+)NCBI
RefSeq Acc Id: XM_039085177   ⟹   XP_038941105
Rat AssemblyChrPosition (strand)Source
GRCr81083,907,491 - 83,931,022 (+)NCBI
mRatBN7.21083,411,197 - 83,434,236 (+)NCBI
RefSeq Acc Id: NP_058699   ⟸   NM_017003
- Peptide Label: precursor
- UniProtKB: Q8K3F9 (UniProtKB/TrEMBL),   F7F923 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000009116   ⟸   ENSRNOT00000009114
RefSeq Acc Id: ENSRNOP00000068582   ⟸   ENSRNOT00000078744
RefSeq Acc Id: ENSRNOP00000040591   ⟸   ENSRNOT00000049070
RefSeq Acc Id: XP_038941105   ⟸   XM_039085177
- Peptide Label: isoform X2
RefSeq Acc Id: XP_038941104   ⟸   XM_039085176
- Peptide Label: isoform X1
- UniProtKB: F7F923 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000064298   ⟸   ENSRNOT00000071765
Protein Domains
Protein kinase

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-M0R4L1-F1-model_v2 AlphaFold M0R4L1 1-706 view protein structure
AF-P06494-F1-model_v2 AlphaFold P06494 1-1257 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13697660
Promoter ID:EPDNEW_R8185
Type:initiation region
Description:erb-b2 receptor tyrosine kinase 2
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.01086,367,528 - 86,367,588EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2561 AgrOrtholog
BioCyc Gene G2FUF-23368 BioCyc
Ensembl Genes ENSRNOG00000006450 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOG00000049238 Ensembl
Ensembl Transcript ENSRNOT00000049070 ENTREZGENE
  ENSRNOT00000049070.4 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cytochrome c1, transmembrane anchor, C-terminal UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor like domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transferase(Phosphotransferase) domain 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Furin-like_Cys-rich_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Furin_repeat UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GF_recep_IV UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Growth_fac_rcpt_cys_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Rcpt_L-dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Rcpt_L-dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TM_ErbB1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_EGF/ERB/XmrK_rcpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24337 UniProtKB/TrEMBL
Pfam Furin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GF_recep_IV UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Pkinase_Tyr UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Recep_L_domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TM_ErbB1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Erbb2 PhenoGen
PIRSF TyrPK_EGF-R UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000006450 RatGTEx
  ENSRNOG00000049238 RatGTEx
SMART SM00261 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP L domain-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF57184 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ERBB2_RAT UniProtKB/Swiss-Prot
UniProt Secondary Q6P732 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2021-03-09 Erbb2  erb-b2 receptor tyrosine kinase 2  LOC102552659  receptor tyrosine-protein kinase erbB-2-like  Data merged from RGD:7499005 737654 PROVISIONAL
2015-07-23 Erbb2  erb-b2 receptor tyrosine kinase 2  Erbb2  v-erb-b2 avian erythroblastic leukemia viral oncogene 2  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2013-12-17 LOC102552659  receptor tyrosine-protein kinase erbB-2-like      Symbol and Name status set to provisional 70820 PROVISIONAL
2013-07-18 Erbb2  v-erb-b2 avian erythroblastic leukemia viral oncogene 2  Erbb2  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2013-07-18 Erbb2  v-erb-b2 avian erythroblastic leukemia viral oncogene 2  Erbb2  v-erb-b2 avian erythroblastic leukemia viral oncogene 2  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2004-09-10 Erbb2  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)    v-erb-b2 erythroblastic leukemia viral oncogene homolog 2  Name updated 1299863 APPROVED
2002-06-10 Erbb2  Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_disease upregulated in endometrial cancer 70349
gene_disease overexpression of the human homolog is associated with breast cancer and other cancers 728778
gene_product member of the epidermal growth factor receptor family of receptor tyrosine kinases 728778